WEBbook of Biologic Therapies | Clinical Immunology Society

Oprelvekin

Brand Name

Neumega

Other Names

Interleukin-11, rhIL-11

Molecular Structure

recombinant, human IL-11

Licensed Indication, Major Target Diseases

risk of, or pre-existing, severe thrombocytopenia and/or need for platelet transfusions following myelosuppressive chemotherapy in patients with nonmyeloid malignancies

Manufacturer/Distributor

Wyeth

References

 Source  Link  Revision Date
 Access Date
Neumega Prescribing Information
http://www.wyeth.com/products?produc..._overview.html  2006-September  2008-June-03
Tags
none

Files (0)

 
You must login to post a comment.

NO RELIANCE FOR MEDICAL DECISIONS

Information, services and/or other features contained in this web site (including any electronic bulletin board contained therein) are being provided for general educational and informational purposes only and are not intended to be a substitute for independent medical judgment or constitute case-specific medical advice or treatment in any way. Such information, services and/or features are not intended to serve as the primary basis for making personal or professional medical decisions, nor are they intended to be a substitute for professional medical advice. Always seek the advice of your physician or other qualified health provider prior to making any treatment or diagnosis decisions and with any questions you may have regarding a medical condition or its diagnosis or treatment. You should confirm any information obtained from this site with other sources before undertaking any treatment or otherwise taking any actions relating thereto. Any reliance on any information, services or other features contained in this site is solely at your own risk.


Clinical Immunology Society
555 East Wells Street, Suite 1100
Milwaukee, WI 53202-3823 USA
Phone: 414/224-8095 | Fax: 414/272-6070
Email: info@clinimmsoc.org

© 2001-2011 Clinical Immunology Society  |  Web Site Disclaimer